These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 12622758

  • 21. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [Abstract] [Full Text] [Related]

  • 22. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
    Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M, AZTEC Study Group.
    Gastroenterology; 2013 Oct; 145(4):766-74.e1. PubMed ID: 23770132
    [Abstract] [Full Text] [Related]

  • 23. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease.
    Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C.
    Cochrane Database Syst Rev; 2000 Oct; (2):CD000545. PubMed ID: 10796557
    [Abstract] [Full Text] [Related]

  • 24. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
    Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, Modigliani R, Rambaud JC.
    Lancet; 1996 Jan 27; 347(8996):215-9. PubMed ID: 8551879
    [Abstract] [Full Text] [Related]

  • 25. Methotrexate for maintenance of remission in Crohn's disease.
    Patel V, Macdonald JK, McDonald JW, Chande N.
    Cochrane Database Syst Rev; 2009 Oct 07; (4):CD006884. PubMed ID: 19821390
    [Abstract] [Full Text] [Related]

  • 26. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
    Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H.
    Am J Gastroenterol; 2001 Mar 07; 96(3):782-7. PubMed ID: 11280551
    [Abstract] [Full Text] [Related]

  • 27. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA, McDonald JW, Feagan BG.
    Cochrane Database Syst Rev; 2005 Jan 25; (1):CD003459. PubMed ID: 15674908
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R, Preiss JC, MacDonald JK, Timmer A.
    Cochrane Database Syst Rev; 2015 May 05; (5):CD007572. PubMed ID: 25942580
    [Abstract] [Full Text] [Related]

  • 31. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA, McDonald JW, Feagan BG.
    Cochrane Database Syst Rev; 2003 May 05; (1):CD003459. PubMed ID: 12535475
    [Abstract] [Full Text] [Related]

  • 32. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM.
    Dan Med Bull; 2011 Dec 05; 58(12):B4360. PubMed ID: 22142578
    [Abstract] [Full Text] [Related]

  • 33. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.
    Aliment Pharmacol Ther; 2002 Oct 05; 16(10):1761-70. PubMed ID: 12269969
    [Abstract] [Full Text] [Related]

  • 34. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease.
    Herrlinger KR, Fellermann K, Fischer C, Kreisel W, Deibert P, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Greinwald R, Stange EF, Schwab M.
    Aliment Pharmacol Ther; 2004 Jun 15; 19(12):1269-76. PubMed ID: 15191508
    [Abstract] [Full Text] [Related]

  • 35. Acute sinusoidal obstruction syndrome after 6-thioguanine therapy for Crohn's disease.
    Kane S, Cohen SM, Hart J.
    Inflamm Bowel Dis; 2004 Sep 15; 10(5):652-4. PubMed ID: 15472529
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
    Egan LJ, Sandborn WJ, Tremaine WJ.
    Am J Gastroenterol; 1998 Mar 15; 93(3):442-8. PubMed ID: 9517654
    [Abstract] [Full Text] [Related]

  • 38. Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study.
    Simsek M, Schepers F, Kaplan S, van Asseldonk D, van Boeckel P, Boekema P, Dijkstra G, Fidder H, Gisbertz I, Hoentjen F, Jharap B, Kubben F, de Leest M, Meijssen M, Petrak A, van de Poel E, Russel M, van Bodegraven AA, Mulder CJJ, de Boer N.
    J Crohns Colitis; 2023 Jun 16; 17(6):933-942. PubMed ID: 36702552
    [Abstract] [Full Text] [Related]

  • 39. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children.
    Jeshion WC, Larsen KL, Jawad AF, Piccoli DA, Verma R, Maller ES, Baldassano RN.
    J Clin Gastroenterol; 2000 Apr 16; 30(3):294-8. PubMed ID: 10777191
    [Abstract] [Full Text] [Related]

  • 40. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK, McDonald JW.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD006097. PubMed ID: 16856112
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.